Related Experiment Videos
Targeting T cells against brain tumors with a bispecific ligand-antibody conjugate
1Department of Biochemistry, University of Illinois, Urbana 61801-3792, USA. e-roy@uiuc.edu
Abstract:
High-affinity receptors expressed on the surface of some tumors can be exploited by chemically conjugating the ligand for the receptor and an antibody against immune effector cells, thus redirecting their cytolytic potential against the tumor. Ovarian carcinomas and some brain tumors express the high-affinity folate receptor (FR). In this report, a transgenic mouse model that generates endogenously arising choroid plexus tumors was used to show that folate/anti-T-cell receptor antibody conjugates can direct infiltration of T cells into solid brain tumor masses. An engineered single-chain Fv form of the anti-T-cell receptor antibody KJ16 was conjugated with folate, to produce a bispecific agent that was substantially smaller than most previously characterized bispecific antibodies. Folate conjugation to the antibody increased T-cell infiltration into the tumors by 10- to 20-fold, and significantly prolonged survival of the mice.
Insights
Researchers developed a novel folate-conjugated antibody to target brain tumors. This approach significantly enhanced T-cell infiltration into tumors, prolonging mouse survival.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Certain tumors, including ovarian carcinomas and some brain tumors, express high-affinity folate receptors (FR).
- Targeting these FRs offers a potential strategy for cancer therapy by redirecting immune cells.
Purpose of the Study:
- To investigate the efficacy of folate-conjugated antibodies in redirecting T cells against brain tumors.
- To develop a bispecific agent smaller than conventional antibodies for enhanced tumor targeting.
Main Methods:
- Utilized a transgenic mouse model with endogenous choroid plexus tumors.
- Engineered a bispecific agent by conjugating folate with a single-chain Fv form of the anti-T-cell receptor antibody KJ16.
- Assessed T-cell infiltration and survival rates in tumor-bearing mice.
Main Results:
- Folate conjugation significantly increased T-cell infiltration into solid brain tumor masses (10- to 20-fold).
- The bispecific folate-antibody conjugate demonstrated a substantial therapeutic effect, significantly prolonging mouse survival.
- The engineered agent was notably smaller than previously described bispecific antibodies.
Conclusions:
- Folate-conjugated antibodies represent a promising strategy for enhancing T-cell-mediated tumor immunotherapy.
- This approach effectively targets brain tumors expressing folate receptors and improves therapeutic outcomes.
- The development of smaller bispecific agents offers advantages in drug delivery and efficacy.